USPTO serial 79344895
MOGANSHAN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 19, 2024
- Examiner
- WOOD, DANIEL PAUL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MOGANSHAN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Zhejiang Zhebei Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Zhejiang Zhebei Pharmaceutical Co., Ltd.
Zhejiang Zhebei Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Zhejiang Zhebei Pharmaceutical Co., Ltd.
Zhejiang Zhebei Pharmaceutical Co., Ltd.
CN
Other trademarks owned by Zhejiang Zhebei Pharmaceutical Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Prakash NAMA
Prakash NAMA Global IP Services, PLLC121 Moore St.Princeton, NJ 08540UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drugs for medical purposes, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Drugs for medical purposes, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Drugs for medical purposes, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Drugs for medical purposes, namely, anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Drugs for medical purposes, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antibiotics; Drugs for medical purposes, namely, adjuvant treatment of acute and chronic hepatitis; Pharmaceutical preparations, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Pharmaceutical preparations, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Pharmaceutical preparations, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Pharmaceutical preparations, namely, anticancer for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Pharmaceutical preparations, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Pharmaceutical preparations, namely, adjuvant treatment of acute and chronic hepatitis; Antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Zhejiang Zhebei Pharmaceutical Co., Ltd.
- Other trademarks owned by Zhejiang Zhebei Pharmaceutical Co., Ltd.
- Other trademarks owned by Zhejiang Zhebei Pharmaceutical Co., Ltd.
- Other trademarks in Class 005
- Similar marks named MOGANSHAN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 21, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 21, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 20, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 19, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 19, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 7, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 2, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 2, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 2, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 20, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 20, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 13, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 13, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 13, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 22, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 16, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 16, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 16, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 16, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 10, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 10, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 10, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 10, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 26, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 26, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 18, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 31, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 31, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 1, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 31, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 19, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 14, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |